PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 142 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2018. The put-call ratio across all filers is 1.87 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,860,000 | -23.6% | 550,700 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $5,055,000 | -9.5% | 550,700 | -4.2% | 0.00% | 0.0% |
| Q1 2021 | $5,587,000 | +5.1% | 574,778 | +10.9% | 0.00% | 0.0% |
| Q4 2020 | $5,318,000 | +1922.1% | 518,306 | +2406.4% | 0.00% | – |
| Q2 2019 | $263,000 | -67.2% | 20,679 | 0.0% | 0.00% | – |
| Q1 2019 | $802,000 | +269.6% | 20,679 | +93.6% | 0.00% | – |
| Q4 2018 | $217,000 | -59.7% | 10,680 | +34.8% | 0.00% | – |
| Q1 2018 | $539,000 | -77.4% | 7,920 | -67.2% | 0.00% | -100.0% |
| Q4 2017 | $2,386,000 | +119.9% | 24,140 | +166.4% | 0.00% | – |
| Q3 2017 | $1,085,000 | -99.3% | 9,062 | -99.5% | 0.00% | -100.0% |
| Q2 2017 | $149,207,000 | +58.0% | 1,707,163 | -32.8% | 0.04% | +52.2% |
| Q1 2017 | $94,464,000 | +29.9% | 2,539,350 | +7.2% | 0.02% | +27.8% |
| Q4 2016 | $72,714,000 | +54.3% | 2,368,538 | +237.0% | 0.02% | +50.0% |
| Q3 2016 | $47,129,000 | +12434.3% | 702,894 | +5468.4% | 0.01% | – |
| Q2 2016 | $376,000 | +5.9% | 12,623 | +4.6% | 0.00% | – |
| Q1 2016 | $355,000 | -95.7% | 12,072 | -88.6% | 0.00% | -100.0% |
| Q4 2015 | $8,295,000 | -11.7% | 105,804 | -15.1% | 0.00% | -33.3% |
| Q3 2015 | $9,393,000 | -33.8% | 124,640 | +2.6% | 0.00% | -25.0% |
| Q2 2015 | $14,184,000 | -89.7% | 121,486 | -79.3% | 0.00% | -88.9% |
| Q1 2015 | $138,334,000 | +259.2% | 585,884 | +188.0% | 0.04% | +260.0% |
| Q4 2014 | $38,508,000 | +0.4% | 203,455 | +26.6% | 0.01% | -9.1% |
| Q3 2014 | $38,343,000 | +175.7% | 160,721 | -23.7% | 0.01% | +175.0% |
| Q2 2014 | $13,906,000 | -68.8% | 210,701 | -50.8% | 0.00% | -66.7% |
| Q1 2014 | $44,591,000 | -10.5% | 428,185 | -11.0% | 0.01% | -14.3% |
| Q4 2013 | $49,800,000 | +19.9% | 481,026 | -37.8% | 0.01% | +7.7% |
| Q3 2013 | $41,518,000 | +10.5% | 773,726 | -8.6% | 0.01% | +8.3% |
| Q2 2013 | $37,560,000 | – | 846,495 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |